David C. Bomberger

Target Discovery, Inc. provides scientific research services. It discovers, validates, and utilizes protein isoforms to improve clinical diagnosis and the management of diseases. The firm’s products address prostate cancer aggressiveness, and chemotherapy selection in breast and ovarian cancer. The company was founded by Luke V. Schneider in 1999 and is headquartered in Palo Alto, CA.

Target Discovery, Inc. provides scientific research services. It discovers, validates, and utilizes protein isoforms to improve clinical diagnosis and the management of diseases. The firm’s products address prostate cancer aggressiveness, and chemotherapy selection in breast and ovarian cancer. The company was founded by Luke V. Schneider in 1999 and is headquartered in Palo Alto, CA.

Target Discovery, Inc. provides scientific research services. It discovers, validates, and utilizes protein isoforms to improve clinical diagnosis and the management of diseases. The firm’s products address prostate cancer aggressiveness, and chemotherapy selection in breast and ovarian cancer. The company was founded by Luke V. Schneider in 1999 and is headquartered in Palo Alto, CA.

Target Discovery, Inc. provides scientific research services. It discovers, validates, and utilizes protein isoforms to improve clinical diagnosis and the management of diseases. The firm’s products address prostate cancer aggressiveness, and chemotherapy selection in breast and ovarian cancer. The company was founded by Luke V. Schneider in 1999 and is headquartered in Palo Alto, CA.

Target Discovery, Inc. provides scientific research services. It discovers, validates, and utilizes protein isoforms to improve clinical diagnosis and the management of diseases. The firm’s products address prostate cancer aggressiveness, and chemotherapy selection in breast and ovarian cancer. The company was founded by Luke V. Schneider in 1999 and is headquartered in Palo Alto, CA.